Bullfrog AI Holdings, Inc. Share Price & Technical Analysis
BFRG · $0.72 (+10.77%)
Healthcare / Health Information Services
$0.72
+10.77%
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also …
Price chart
Seasonality
May has 1 positive and 2 negative years (last 4 years shown)
0% return in May, -3% avg return in past 3 year May month.
157% return in 2026, -27% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -33% | 0% | 240% | -50% | 0% | – | – | – | – | – | – | – | 157% |
| 25 | 10% | -9% | -33% | 6% | -6% | -12% | -7% | -14% | 17% | -7% | -23% | -10% | -88% |
| 24 | 53% | 29% | -35% | -3% | -9% | -41% | 58% | -10% | 12% | -21% | -4% | -5% | 23% |
| 23 | – | -54% | 13% | 29% | 7% | -27% | 40% | -33% | -3% | -12% | 7% | 18% | -15% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Downtrend · Strong
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$11.49M
P/E ratio
—
52W high
$2.04
52W low
$0.42
Volume
2,21,977
Beta
-3.00
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Bullfrog AI Holdings, Inc. share price today?
- Bullfrog AI Holdings, Inc. (BFRG) last traded around $0.72 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BFRG have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BFRG. Download the app for real-time alerts.
- How can I analyze Bullfrog AI Holdings, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.